Wenbo Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wenbo Wu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Yu Wang
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 shared publications Tingyu Liang
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 shared publicationsXiaoman Kang
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 shared publicationsYiming Lian
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 shared publications- Chunhua Hu
National Engineering Research Center of Neuromodulation, School of Aerospace Engineering, Tsinghua University, Beijing, 100084, China
2 shared publications Hao Xing
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China
2 shared publications
Latest Publications
- Open Access
- 9 July 2026
- Published by Elsevier in Cancer Letters
- Vol. 657, 218717
Ferroptosis-resistant myeloid niche shapes tumor natural evolution in glioblastoma
- 9 July 2026
- Published by Elsevier in Cancer Letters
- Vol. 657, 218717
Open AccessFerroptosis-resistant myeloid niche shapes tumor natural evolution in glioblastoma
- Open Access
- 17 June 2026
- Published by Elsevier in Brain Stimulation
- Vol. 19 (4) , 103141
Intracranial-implanted coupled electrode tumor treating fields (ICE-TTF) enable efficient and directionally tunable electric-field delivery for glioma
- 17 June 2026
- Published by Elsevier in Brain Stimulation
- Vol. 19 (4) , 103141
Open AccessIntracranial-implanted coupled electrode tumor treating fields (ICE-TTF) enable efficient and directionally tunable electric-field delivery for glioma
- Open Access
- 30 April 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1014
Identification of RPA3 as a Potential Functional Effector of Chromosome 7 Gain in Glioblastoma
Background: Chromosome 7 gain (chr7 gain) is a highly prevalent early event in glioblastoma (GBM). Because chr7 gain usually involves broad chromosomal amplification, its biological impact is unlikely to be fully explained by canonical loci such as EGFR and MET. The contribution of less-characterized, dosage-sensitive genes on chromosome 7 remains insufficiently defined. This study aimed to identify additional chr7 candidates associated with malignant phenotypes in GBM. Methods: Transcriptomic, copy-number, and clinical data from TCGA-GBM and TCGA-LGG were analyzed to characterize chr7-gain-associated alterations and prioritize candidate genes. Refined GBM and histologic GBM cohorts based on the WHO 2021 framework were used for candidate selection. RPA3-associated pathway features were examined using ssGSEA, PROGENy, WGCNA, and protein–protein interaction analysis, with external validation in the CGGA-693 cohort. Single-cell RNA-seq analysis compared chr7-gain and chr7-normal-copy tumor subclusters. Functional relevance was evaluated by siRNA-mediated knockdown in U87 and U118 cells. Results: Chr7 gain was enriched in high-grade IDH-wildtype gliomas and was associated with cell-cycle- and DNA repair-related programs. RPA3 was prioritized as a dosage-sensitive chromosome 7 candidate based on its upregulation in chr7-gain tumors, association with poor prognosis, and concordance with replication- and repair-related signatures. In vitro, RPA3 knockdown impaired cell growth, proliferation, colony formation, and migration. Single-cell analysis suggested greater transcriptomic and network-level relevance of RPA3 in chr7-gain tumor cells. Conclusions: RPA3 is a dosage-sensitive chromosome 7 candidate associated with aggressive and replication-/repair-related phenotypes in GBM. Increased RPA3 expression may contribute to the selective advantage associated with chr7 gain, which supports further investigation as potential therapeutic target.
- 30 April 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 1014
Open AccessIdentification of RPA3 as a Potential Functional Effector of Chromosome 7 Gain in Glioblastoma
Background: Chromosome 7 gain (chr7 gain) is a highly prevalent early event in glioblastoma (GBM). Because chr7 gain usually involves broad chromosomal amplification, its biological impact is unlikely to be fully explained by canonical loci such as EGFR and MET. The contribution of less-characterized, dosage-sensitive genes on chromosome 7 remains insufficiently defined. This study aimed to identify additional chr7 candidates associated with malignant phenotypes in GBM. Methods: Transcriptomic, copy-number, and clinical data from TCGA-GBM and TCGA-LGG were analyzed to characterize chr7-gain-associated alterations and prioritize candidate genes. Refined GBM and histologic GBM cohorts based on the WHO 2021 framework were used for candidate selection. RPA3-associated pathway features were examined using ssGSEA, PROGENy, WGCNA, and protein–protein interaction analysis, with external validation in the CGGA-693 cohort. Single-cell RNA-seq analysis compared chr7-gain and chr7-normal-copy tumor subclusters. Functional relevance was evaluated by siRNA-mediated knockdown in U87 and U118 cells. Results: Chr7 gain was enriched in high-grade IDH-wildtype gliomas and was associated with cell-cycle- and DNA repair-related programs. RPA3 was prioritized as a dosage-sensitive chromosome 7 candidate based on its upregulation in chr7-gain tumors, association with poor prognosis, and concordance with replication- and repair-related signatures. In vitro, RPA3 knockdown impaired cell growth, proliferation, colony formation, and migration. Single-cell analysis suggested greater transcriptomic and network-level relevance of RPA3 in chr7-gain tumor cells. Conclusions: RPA3 is a dosage-sensitive chromosome 7 candidate associated with aggressive and replication-/repair-related phenotypes in GBM. Increased RPA3 expression may contribute to the selective advantage associated with chr7 gain, which supports further investigation as potential therapeutic target.
- Open Access
- 20 March 2026
- Published by Elsevier in SSRN Electronic Journal
Intracranial-Implanted Coupled Electrode Tumor Treating Fields (ICE-TTF) Enable Efficient and Directionally Tunable Electric-Field Therapy for Glioma
BackgroundTumor treating fields (TTFields) improve survival in glioblastoma (GBM), but their clinical efficacy is limited by inefficient electric-field delivery through the high-impedance scalp and skull. This attenuation reduces intratumoral electric field, increases superficial heating, and contributes to treatment-related dermatologic toxicity.MethodsWe propose an intracranial-implanted coupled-electrode TTFields strategy (ICE-TTF), in which a single depth electrode implanted in the tumor cavity is coupled with distributed extracranial counter-electrodes. Finite-element modeling was used to optimize electrode geometry and evaluate electric-field and thermal distributions. A segmented intracranial electrode was examined for directional field switching. Therapeutic efficacy was assessed in rat glioma models using bioluminescence imaging and histology. Impedance monitoring and electrochemical assays were performed to evaluate interface behavior and electrode safety.ResultsICE-TTF generated therapeutically relevant tumor electric fields with substantially lower power and minimal temperature rise compared with external TTFields. Segmented contacts enabled switching between predominantly radial and tangential field components. In vivo, ICE-TTF suppressed tumor growth and reduced proliferative activity. Electrode–tissue impedance correlated with tumor progression, supporting its potential as a monitoring biomarker. Electrochemical modeling, ion-release measurements, and histology confirmed the stability and biocompatibility of PtIr electrodes under high-frequency stimulation.ConclusionsICE-TTF introduces an intracranial–extracranial coupled electrode architecture that improves TTFields energy delivery efficiency using a single implanted electrode while enabling directional field modulation and impedance-based monitoring. This strategy may provide a minimally invasive and energy-efficient platform for adaptive electric-field therapy in glioblastoma.
- 20 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIntracranial-Implanted Coupled Electrode Tumor Treating Fields (ICE-TTF) Enable Efficient and Directionally Tunable Electric-Field Therapy for Glioma
BackgroundTumor treating fields (TTFields) improve survival in glioblastoma (GBM), but their clinical efficacy is limited by inefficient electric-field delivery through the high-impedance scalp and skull. This attenuation reduces intratumoral electric field, increases superficial heating, and contributes to treatment-related dermatologic toxicity.MethodsWe propose an intracranial-implanted coupled-electrode TTFields strategy (ICE-TTF), in which a single depth electrode implanted in the tumor cavity is coupled with distributed extracranial counter-electrodes. Finite-element modeling was used to optimize electrode geometry and evaluate electric-field and thermal distributions. A segmented intracranial electrode was examined for directional field switching. Therapeutic efficacy was assessed in rat glioma models using bioluminescence imaging and histology. Impedance monitoring and electrochemical assays were performed to evaluate interface behavior and electrode safety.ResultsICE-TTF generated therapeutically relevant tumor electric fields with substantially lower power and minimal temperature rise compared with external TTFields. Segmented contacts enabled switching between predominantly radial and tangential field components. In vivo, ICE-TTF suppressed tumor growth and reduced proliferative activity. Electrode–tissue impedance correlated with tumor progression, supporting its potential as a monitoring biomarker. Electrochemical modeling, ion-release measurements, and histology confirmed the stability and biocompatibility of PtIr electrodes under high-frequency stimulation.ConclusionsICE-TTF introduces an intracranial–extracranial coupled electrode architecture that improves TTFields energy delivery efficiency using a single implanted electrode while enabling directional field modulation and impedance-based monitoring. This strategy may provide a minimally invasive and energy-efficient platform for adaptive electric-field therapy in glioblastoma.
- Open Access
- 9 November 2024
- Published by MDPI AG in Preprints.org
Individualized Radiotherapy Timing for Postoperative Diffuse Low-Grade Glioma Patients: Managing Side Effects and Decisions
This review explores the nuanced decision-making surrounding postoperative radiotherapy for diffuse low-grade glioma patients, emphasizing the need for individualized treatment to balance the benefits of tumor control with the risks of side effects. Radiotherapy is a cornerstone of diffuse low-grade glioma treatment, offering significant improvements in progression-free survival, but its potential for quality of life necessitates careful consideration of individual patient factors. The review delves into the radiotherapy timing, revealing that while early radiotherapy enhances progression-free survival, it does not significantly impact overall survival and may lead to severe and prolonged decline in long-term quality of life. Conversely, delayed radiotherapy may mitigate these side effects. The review advocates for a patient-centered approach, emphasizing the importance of weighing individual risks and benefits, and highlights the potential of artificial intelligence in predicting quality of life and the need to revisit previous research findings in light of the 2021 WHO (World Health Organization) classification update, underscoring the evolving nature of low-grade glioma treatment and the ongoing quest for optimal therapeutic strategies.
- 9 November 2024
- Published by MDPI AG in Preprints.org
Open AccessIndividualized Radiotherapy Timing for Postoperative Diffuse Low-Grade Glioma Patients: Managing Side Effects and Decisions
This review explores the nuanced decision-making surrounding postoperative radiotherapy for diffuse low-grade glioma patients, emphasizing the need for individualized treatment to balance the benefits of tumor control with the risks of side effects. Radiotherapy is a cornerstone of diffuse low-grade glioma treatment, offering significant improvements in progression-free survival, but its potential for quality of life necessitates careful consideration of individual patient factors. The review delves into the radiotherapy timing, revealing that while early radiotherapy enhances progression-free survival, it does not significantly impact overall survival and may lead to severe and prolonged decline in long-term quality of life. Conversely, delayed radiotherapy may mitigate these side effects. The review advocates for a patient-centered approach, emphasizing the importance of weighing individual risks and benefits, and highlights the potential of artificial intelligence in predicting quality of life and the need to revisit previous research findings in light of the 2021 WHO (World Health Organization) classification update, underscoring the evolving nature of low-grade glioma treatment and the ongoing quest for optimal therapeutic strategies.